{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:49:20Z","timestamp":1762098560833},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T00:00:00Z","timestamp":1524182400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00392-018-1242-2","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T11:14:14Z","timestamp":1524222854000},"page":"533-538","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?"],"prefix":"10.1007","volume":"107","author":[{"given":"D.","family":"Duerschmied","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Darius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. A.","family":"Katus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Rottbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,20]]},"reference":[{"issue":"25","key":"1242_CR1","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375(25):2423\u20132434. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1611594","journal-title":"N Engl J Med"},{"issue":"16","key":"1242_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH, Investigators R-DPSCa (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377(16):1513\u20131524. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1708454","journal-title":"N Engl J Med"},{"issue":"38","key":"1242_CR3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893\u20132962. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw210","journal-title":"Eur Heart J"},{"issue":"23","key":"1242_CR4","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","volume":"339","author":"MB Leon","year":"1998","unstructured":"Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339(23):1665\u20131671. \n                    https:\/\/doi.org\/10.1056\/NEJM199812033392303","journal-title":"N Engl J Med"},{"key":"1242_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320","author":"M Authors\/Task Force","year":"2015","unstructured":"Authors\/Task Force M, Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S (2015) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv320","journal-title":"Eur Heart J"},{"issue":"37","key":"1242_CR6","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"F Authors\/Task","year":"2014","unstructured":"Authors\/Task F, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014) 2014 ESC\/EACTS guidelines on myocardial revascularization: the Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35(37):2541\u20132619. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehu278","journal-title":"Eur Heart J"},{"issue":"20","key":"1242_CR7","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van\u2019t Hof A, Widimsky P, Zahger D (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33(20):2569\u20132619. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehs215\n                    \n                   pii].","journal-title":"Eur Heart J"},{"key":"1242_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw058","author":"H Heidbuchel","year":"2016","unstructured":"Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, Advisors (2016) Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw058","journal-title":"Eur Heart J"},{"key":"1242_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht461","author":"M Moser","year":"2013","unstructured":"Moser M, Olivier CB, Bode C (2013) Triple antithrombotic therapy in cardiac patients: more questions than answers. Eur Heart J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/eht461","journal-title":"Eur Heart J"},{"issue":"10","key":"1242_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","volume":"126","author":"M Lamberts","year":"2012","unstructured":"Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Kober L, Torp-Pedersen C, Gislason GH, Hansen ML (2012) Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 126(10):1185\u20131193. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.114967","journal-title":"Circulation"},{"issue":"6","key":"1242_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s00392-016-1071-0","volume":"106","author":"M Proietti","year":"2017","unstructured":"Proietti M, Airaksinen KEJ, Rubboli A, Schlitt A, Kiviniemi T, Karjalainen PP, Lip GYH, Group AS (2017) Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. Clin Res Cardiol 106(6):420\u2013427. \n                    https:\/\/doi.org\/10.1007\/s00392-016-1071-0","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"1242_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00392-016-1052-3","volume":"106","author":"P Ruile","year":"2017","unstructured":"Ruile P, Jander N, Blanke P, Schoechlin S, Reinohl J, Gick M, Rothe J, Langer M, Leipsic J, Buettner HJ, Neumann FJ, Pache G (2017) Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation. Clin Res Cardiol 106(2):85\u201395. \n                    https:\/\/doi.org\/10.1007\/s00392-016-1052-3","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"1242_CR13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s00392-016-0999-4","volume":"105","author":"M Proietti","year":"2016","unstructured":"Proietti M, Nobili A, Raparelli V, Napoleone L, Mannucci PM, Lip GY, investigators R (2016) Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. Clin Res Cardiol 105(11):912\u2013920. \n                    https:\/\/doi.org\/10.1007\/s00392-016-0999-4","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"1242_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00392-016-1040-7","volume":"106","author":"L Fauchier","year":"2017","unstructured":"Fauchier L, Clementy N, Bisson A, Stamboul K, Ivanes F, Angoulvant D, Babuty D, Lip GY (2017) Prognosis in patients with atrial fibrillation and a presumed \u201ctemporary cause\u201d in a community-based cohort study. Clin Res Cardiol 106(3):202\u2013210. \n                    https:\/\/doi.org\/10.1007\/s00392-016-1040-7","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"1242_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00392-016-1021-x","volume":"106","author":"M Gunawardene","year":"2017","unstructured":"Gunawardene M, Willems S, Schaffer B, Moser J, Akbulak RO, Jularic M, Eickholt C, Nuhrich J, Meyer C, Kuklik P, Sehner S, Czerner V, Hoffmann BA (2017) Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation. Clin Res Cardiol 106(1):38\u201348. \n                    https:\/\/doi.org\/10.1007\/s00392-016-1021-x","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"1242_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00392-015-0910-8","volume":"105","author":"J Seeger","year":"2016","unstructured":"Seeger J, Bothner C, Dahme T, Gonska B, Scharnbeck D, Markovic S, Rottbauer W, Wohrle J (2016) Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk. Clin Res Cardiol 105(3):225\u2013229. \n                    https:\/\/doi.org\/10.1007\/s00392-015-0910-8","journal-title":"Clin Res Cardiol"},{"key":"1242_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-017-1179-x","author":"BE Stahli","year":"2017","unstructured":"Stahli BE, Gebhard C, Gick M, Ferenc M, Mashayekhi K, Buettner HJ, Neumann FJ, Toma A (2017) Outcomes after percutaneous coronary intervention for chronic total occlusion according to baseline renal function. Clin Res Cardiol. \n                    https:\/\/doi.org\/10.1007\/s00392-017-1179-x","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"1242_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00392-017-1102-5","volume":"106","author":"R Caterina De","year":"2017","unstructured":"De Caterina R, Lip GYH (2017) The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol 106(8):565\u2013572. \n                    https:\/\/doi.org\/10.1007\/s00392-017-1102-5","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"1242_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s00392-017-1098-x","volume":"106","author":"SH Hohnloser","year":"2017","unstructured":"Hohnloser SH, Basic E, Nabauer M (2017) Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Clin Res Cardiol 106(8):618\u2013628. \n                    https:\/\/doi.org\/10.1007\/s00392-017-1098-x","journal-title":"Clin Res Cardiol"},{"issue":"9872","key":"1242_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van\u2019t Hof AW, ten Berg JM, Investigators Ws (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381(9872):1107\u20131115. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)62177-1","journal-title":"Lancet"},{"issue":"16","key":"1242_CR21","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","volume":"65","author":"KA Fiedler","year":"2015","unstructured":"Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sarafoff N (2015) Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 65(16):1619\u20131629. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2015.02.050","journal-title":"J Am Coll Cardiol"},{"issue":"45","key":"1242_CR22","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"GY Lip","year":"2014","unstructured":"Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Document R, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35(45):3155\u20133179. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehu298","journal-title":"Eur Heart J"},{"issue":"3","key":"1242_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol C, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37(3):267\u2013315. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv320","journal-title":"Eur Heart J"},{"key":"1242_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, Group ESCSD., Guidelines ESCCfP, Societies ESCNC. (2017) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehx419","journal-title":"Eur Heart J"},{"issue":"4","key":"1242_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.116.025783","volume":"135","author":"CM Gibson","year":"2017","unstructured":"Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Burton P, van Eickels M, Korjian S, Daaboul Y, Jain P, Lip GY, Cohen M, Peterson ED, Fox KA (2017) Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy. Circulation 135(4):323\u2013333. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.025783","journal-title":"Circulation"},{"issue":"1","key":"1242_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366(1):9\u201319. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1112277","journal-title":"N Engl J Med"},{"issue":"11","key":"1242_CR27","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00392-017-1128-8","volume":"106","author":"L Schoener","year":"2017","unstructured":"Schoener L, Jellinghaus S, Richter B, Pfluecke C, Ende G, Christoph M, Quick S, Loehn T, Speiser U, Poitz DM, Mierke J, Strasser RH, Ibrahim K (2017) Reversal of the platelet inhibitory effect of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor in vitro: a new approach to an old issue. Clin Res Cardiol 106(11):868\u2013874. \n                    https:\/\/doi.org\/10.1007\/s00392-017-1128-8","journal-title":"Clin Res Cardiol"},{"key":"1242_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30751-1","author":"EM Ohman","year":"2017","unstructured":"Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Guray U, Park DW, Bode C, Welsh RC, Gibson CM (2017) Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)30751-1","journal-title":"Lancet"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-018-1242-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-018-1242-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-018-1242-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T19:09:02Z","timestamp":1555700942000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-018-1242-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,20]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["1242"],"URL":"https:\/\/doi.org\/10.1007\/s00392-018-1242-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,20]]},"assertion":[{"value":"6 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Duerschmied D: Speaker honoraria from Bayer, Daiichi-Sankyo, Pfizer, Brachmann J: none, Darius H: Speaker\u2019s honoraria and consulting fees from Bayer, Bristol-Myers Squibb\/Pfizer, Daiichi-Sankyo, Boehringer Ingelheim, Frey N: none, Katus HA: none, Rottbauer W: none, Sch\u00e4fer A: Speaker honoraria from Daiichi, Bristol-Myers Squibb\/Pfizer; Consulting fees from Bayer, Boehringer Ingelheim, Thiele H: none, Bode C: Research grants from Bayer, GlaxoSmithKline, Merck; Speaker\u2019s honoraria from Bayer, Bristol-Myers Squibb\/Pfizer, Daiichi-Sankyo, Boehringer Ingelheim; Consulting fees from Bayer, Zeymer U: Speaker\u2019s honoraria and consulting fees from Bayer, Bristol-Myers Squibb\/Pfizer, Daiichi-Sankyo, Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}